Anticancer efficacy and toxicity of oral GMO-paclitaxel in a hormone refractory prostate cancer model
- Authors
- Kim, D.B.; Jang, J.; Cho, Y.-H.; Yoon, M.S.; Chung, H.-S.; Park, Y.T.; Choi, Y.W.; Kim, S.W.
- Issue Date
- Feb-2006
- Publisher
- Korean Urological Association
- Keywords
- Hormone refractory prostate cancer; Paclitaxel
- Citation
- Korean Journal of Urology, v.47, no.2, pp 143 - 149
- Pages
- 7
- Journal Title
- Korean Journal of Urology
- Volume
- 47
- Number
- 2
- Start Page
- 143
- End Page
- 149
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/25532
- DOI
- 10.4111/kju.2006.47.2.143
- ISSN
- 0494-4747
- Abstract
- Purpose: We wanted to evaluate the efficacy and toxicity of the newly developed oral glyceryl monooleate (GMO)-paclitaxel in a hormone refractory prostate cancer model. Materials and methods: A paclitaxel formulation was prepared from GMO, tricaprylin, Tween®80 and paclitaxel. The tumor cells of prostate cancer (DU-145 cells) were incubated and then put into different paclitaxel concentrations. The tumoricidal activity was measured by using an indirect methylthiazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) assay. Cells of the DU-145 cell line were subcutaneously heterotransplanted into 18 nude mice, and they developed prostate cancer. The 18 mice were divided into 3 groups; the control group was injected with the DU-145 cell line (n=6), the GMO group was injected with GMO after the DU-145 cells were injected (n=6), and the oral GMO-paclitaxel group was injected with oral GMO-paclitaxel after the DU-145 cells were injected (n=6). The tumor volume was measured every week and the main organs were evaluated pathologically to determine the toxicity. Results: On the MTT assay, the control group and the GMO group did not display cytotoxicity. However, treatment with the various GMO-paclitaxel formulations (0.1 μg/ml, 1 μg/ml, 10 μg/ml) for treating the DU-145 cell line cancer induced cytotoxicity in a dose dependent fashion. The tumor volumes were not significantly changed in the group that was administered oral GMO-paclitaxel. However, there were significantly increased tumor volumes in the control group and the GMO group (p< 0.05). Toxic changes were not detected in liver and kidney, and there was normal cellularity with a normal myeloid:erythroid ratio in the mice after the administration of oral GMO-paclitaxel. Conclusions: The newly developed oral GMO-paclitaxel has a remarkable cytotoxic effect against DU-145 cells without systemic toxicity. Therefore, oral GMO-paclitaxel therapy promises to be a safe and effective modality for treating hormone refractory prostate cancer, and it can possibly replace IV paclitaxel.
- Files in This Item
-
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/25532)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.